Alpha Teknova (TKNO) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alpha Teknova is the larger company by market cap ($480.0 million vs $5.1 million), about 94.6 times the size, while Trinity Biotech is growing revenue faster (+8.3% vs +7.4%). Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -51.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TKNO | TRIB |
|---|---|---|
| Share price | $7.63 | $6.24 |
| Market cap | $479.95M | $5.07M |
| 1-day change | -2.30% | +13.76% |
| YTD return | +100.79% | — |
| 1-year return | +77.44% | — |
| 5-year return | -63.63% | — |
| EPS (TTM) | $-0.30 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | $61.55M |
| Revenue growth (YoY) | +7.35% | +8.31% |
| Net income (latest FY) | $-17.26M | $-31.79M |
| Gross margin | 33.17% | 34.83% |
| Operating margin | -41.90% | -34.38% |
| Net margin | -42.59% | -51.64% |
| 52-week high | $9.48 | $52.50 |
| 52-week low | $1.91 | $4.54 |
| Distance from 52-week high | -19.51% | -88.11% |
| Analyst consensus | none | — |
| Avg. price target upside | +28.83% | — |
| Average volume | 437.31K | 13.54K |
| Shares outstanding | 62.90M | 813.13K |
| Employees | 158 | 287 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alpha Teknova is about 94.6 times larger than Trinity Biotech by market value ($479.95M vs $5.07M).
- Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -51.6 cents for Trinity Biotech.
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 287 employees
TKNO vs TRIB FAQ
Which is bigger, Alpha Teknova or Trinity Biotech?
Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $5.07M for Trinity Biotech (TRIB).
Are Alpha Teknova and Trinity Biotech in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.